If you’re researching wrinkle treatments, you’ve probably come across the terms Jeuveau toxin and Jeuveau Botox. While Jeuveau is often compared to Botox, there’s still a lot of confusion surrounding what it is, how it works, and whether it’s safe.
Let’s set the record straight. Using data from clinical studies, we’re busting the biggest myths about Jeuveau so you can make informed, confident decisions about your skin.
Myth 1: Jeuveau Toxin Is Completely Different From Botox
The Reality: Jeuveau and Botox both use botulinum toxin type A, a purified protein that relaxes facial muscles to smooth wrinkles. The difference? Jeuveau was created specifically for cosmetic use. That’s right, not an off-label medical treatment, just beauty.
Myth 2: “Jeuveau Botox” Is Just a Trendy Name
The Reality: While “Jeuveau Botox” is a common search term, Jeuveau is its own FDA-approved product. It’s not just a rebrand to attract younger clients; it is something different. In fact, it’s sometimes called “Newtox” because it offers a modern alternative to Botox with similar performance and lower cost.
Myth 3: Jeuveau Doesn’t Last As Long As Botox
The Reality: In clinical trials, Jeuveau lasted 3 to 4 months, which is the same as Botox. In some studies using a higher dose (40 units), Jeuveau even lasted up to 6 months, with no additional side effects.
Myth 4: Jeuveau Toxin Works Slower Than Other Injectables
The Reality: Jeuveau may actually work faster than Botox. Results are often visible within 2 to 3 days, while Botox typically takes 3 to 4. In head-to-head trials, Jeuveau ranked among the fastest for the onset of effect compared to other neuromodulators.
Myth 5: Jeuveau Isn’t as Safe
The Reality: Jeuveau was tested on thousands of patients in U.S. and global trials and showed a very low rate of side effects, similar to Botox. Common issues like mild headaches or bruising were rare and temporary.
Myth 6: You Need More Jeuveau to Get Results
The Reality: Although Jeuveau is less expensive than Botox, it uses the same dosing units as Botox to get similar effects. It’s not more diluted, and no extra product is required for results. They actually tout a sophisticated purification technique that makes you less likely to have long-term side effects.
Myth 7: Jeuveau Toxin Is Only for Women
The Reality: Jeuveau is safe and effective for all genders and skin types. In fact, more men are turning to wrinkle-relaxing treatments as part of preventative skincare. Clinical trials included a diverse group of users across age ranges, and all of the results were promising and comparable to Botox.
Final Take: The Truth About Jeuveau Toxin and Jeuveau Botox
Don’t let outdated info or internet rumors fool you, Jeuveau toxin is a scientifically-backed, FDA-approved wrinkle treatment that holds its own against Botox. It works fast, lasts long, and may even save you money without compromising on safety or results.
So whether you call it Jeuveau Botox, Jeuveau toxin, or “Newtox,” one thing is clear: it’s not a myth. It’s a modern option for smoother skin backed by real science.
References
Beer, K.R., Shamban, A.T., Avelar, R.L., Gross, J.E., & Jonker, A. (2019). Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery, 45(12), 1381-1393. DOI: 10.1097/DSS.0000000000001903
Cheon, H.I., Jung, N., Won, C.H., Kim, B.J., & Lee, Y.W. (2019). Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow’s feet: a phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery, 45(12), 1610-1619. DOI: 10.1097/DSS.0000000000001920
Rzany, B.J., Ascher, B., Avelar, R.L., et al. (2020). A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase 3, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthetic Surgery Journal, 40(4), 413-429. DOI: 10.1093/asj/sjz110
Gadarowski, M.B., Ghamrawi, R., Taylor, S.L., & Feldman, S.R. (2021). PrabotulinumtoxinA-xvfs for the treatment of moderate-to-severe glabellar lines: a review of phase II and III clinical trials. Annals of Pharmacotherapy, 55(3), 279-287. DOI: 10.1177/1060028020943527
Avelar, R.L. (2024). Post hoc analysis comparing the safety and efficacy of prabotulinumtoxinA in millennials and nonmillennials with moderate to severe glabellar lines. Dermatologic Surgery, 50(9 Suppl), S42–S47. DOI: 10.1097/DSS.0000000000004249
Lemdani, M.S., Honig, S.E., Habarth-Morales, T.E., et al. (2025). Comparison of botulinum toxin A formulations for glabellar strain treatment in women: a double-blind randomized clinical trial. JAMA Dermatology, 161(7), 723-730. DOI: 10.1001/jamadermatol.2025.1335
Jung, B.K., Park, H., Cheon, Y.W., et al. (2023). Clinical investigation of botulinum toxin (prabotulinumtoxin A) for bruxism related to masseter muscle hypertrophy: a prospective study. Journal of Cranio-Maxillofacial Surgery, 51(5), 332-337. DOI: 10.1016/j.jcms.2023.05.005
Fagien, S., Avelar, R.L., Cox, S.E., Joseph, J.H., Kaufman-Janette, J., & Marcus, K.A. (2024). Safety and duration of effect of 40-unit prabotulinumtoxinA-xvfs for the treatment of moderate to severe glabellar lines in adult patients: a phase II, multicenter, randomized, double-blind, active-controlled trial. Aesthetic Surgery Journal, 44(9), 987-1000. DOI: 10.1093/asj/sjae051
Clifton, M. (2023). PrabotulinumtoxinA-xvfs (Jeuveau, Evolus) for the temporary treatment of glabellar lines: what does this toxin bring to the table? The Dermatology Digest.
European Medicines Agency. (2019). Nuceiva (botulinum toxin type A) – EPAR Product Information. EMA/249428/2019. (Available at EMA website).
